Chongqing Precision Biotech starts small in vivo CAR-T trial in myeloma
The 15-patient Phase 1 study tests an in vivo-generated CAR-T approach against a BCMA-dominated field of ex vivo cell therapies and bispecifics.
Executive Summary
- Chongqing Precision Biotech Co., Ltd has registered a Phase 1 dose-finding study of an in vivo-generated CAR-T therapy in patients with relapsed or refractory multiple myeloma who have exhausted standard treatment lines.
- The therapy aims to produce CAR-T cells inside the patient rather than through the ex vivo manufacturing process that underlies every approved CAR-T product in myeloma today, a manufacturing distinction rather than a proven clinical advantage.
- Cell therapy is a crowded modality in myeloma, with dozens of CAR-T programs in active testing worldwide, but none share this in vivo generation approach in the trials on record.
- As an early, small, single-site safety study, the trial is built to establish tolerability and a workable dose, not to demonstrate efficacy against the responses already reported for approved cell therapies.
The registration
Chongqing Precision Biotech Co., Ltd has registered NCT07715630, a Phase 1 trial evaluating PICX Injection in patients with relapsed or refractory multiple myeloma. The study is described as an in vivo CAR-T therapy, and is designed to assess safety, tolerability, and preliminary efficacy at a single site. The trial targets 15 patients, is recruiting, and carries a stated primary completion date of April 30, 2028. NCT07715630+1In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaNCT07715630Chongqing Precision Biotech Registers Phase 1 Trial of PICX CAR-T Therapy for Relapsed/Refractory Multiple MyelomaJul 20, 2026
What it tests
The trial's primary endpoints are the incidence of adverse events through 28 days after infusion and the maximum tolerated dose, determined from dose-limiting toxicities observed in that same window. Secondary measures include objective response rate, duration of response, progression-free and overall survival, and minimal residual disease negativity, tracked out to 24 months. Enrollment is restricted to patients with disease progression after at least two prior standard regimens, or early relapse after first-line therapy, placing the study in a third-line-or-later population. NCT07715630In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaNCT07715630
The design
"This investigator-initiated, single-center, single-arm study targets 15 patients and is actively recruiting, with a projected primary completion date of April 30, 2028," according to the trial's briefing. The open-label, single-arm design with one treatment group at one site is consistent with an early dose-finding study, not a registrational trial. Chongqing Precision Biotech has completed three prior trials with none terminated, a small but clean record; the sponsor also has 31 trials currently recruiting and 14 in an unknown status across its broader portfolio. Chongqing+1Chongqing Precision Biotech Registers Phase 1 Trial of PICX CAR-T Therapy for Relapsed/Refractory Multiple MyelomaJul 20, 2026In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaNCT07715630
The field it enters
CAR-T cell therapy is an established modality in multiple myeloma, with 183 trials on record using CAR-T cells in the indication. Approved and late-stage cell therapies in the space, including ciltacabtagene autoleucel from Janssen Research & Development and idecabtagene vicleucel from Celgene, target BCMA and rely on ex vivo manufacturing, where cells are extracted, engineered, and expanded outside the body before reinfusion. PICX Injection's in vivo generation approach differs from that manufacturing step across the modality-precedent set; the trial does not disclose a target, so no claim about mechanism-level novelty can be drawn. The broader myeloma field also includes bispecific antibodies against BCMA, such as Pfizer's elranatamab and Regeneron Pharmaceuticals' linvoseltamab, which compete on the same disease but through a different modality and require no cell manufacturing at all. NCT07715630In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaNCT07715630
What would matter
Because in vivo CAR-T generation removes the ex vivo manufacturing and lymphodepletion steps that ex vivo products require, the tolerability data from this dose-finding cohort is the information this trial can realistically produce. A dose that clears the trial's safety bar without dose-limiting toxicity, paired with any early responses in a heavily pretreated population, would be the result that distinguishes an in vivo approach from the ex vivo standard it aims to simplify. NCT07715630In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaNCT07715630
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.